In fact, GH replacement therapy seems to be more suitable than adiponectin administration for the prevention and treatment of NAFLD because adiponectin activity is limited, despite the relatively high plasma concentrations of adiponectin (5-30 μg/ml). The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.